MARKET

TBPH

TBPH

Theravance Bioph
NASDAQ
10.65
+0.17
+1.62%
After Hours: 10.65 0 0.00% 16:03 12/01 EST
OPEN
10.45
PREV CLOSE
10.48
HIGH
10.68
LOW
10.32
VOLUME
408.72K
TURNOVER
0
52 WEEK HIGH
12.03
52 WEEK LOW
8.25
MARKET CAP
530.35M
P/E (TTM)
-11.1893
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TBPH last week (1120-1124)?
Weekly Report · 4d ago
Theravance Bioph: Statement of changes in beneficial ownership of securities
Press release · 11/23 00:05
Weekly Report: what happened at TBPH last week (1113-1117)?
Weekly Report · 11/20 12:03
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
Legend biotech partners with novartis in a $1.2 billion deal to develop and commercialize dll3 car-t candidates. Wuxi xdc, an adc/bioconjugate crdmo, raises $520 million in a successful ipo in hong kong. Shanghai sciclone pharma acquires china rights to menarini group's oral cancer therapy for metastatic breast cancer.
Seeking Alpha · 11/19 07:00
Tracking Seth Klarman's Baupost Group Holdings - Q3 2023 Update
Baupost group's 13f portfolio value decreased from $5.61b to £5.21b this quarter. New positions include clarivate plc, jacobs solutions, liberty media live, and tower semiconductor. The portfolio is heavily concentrated with liberty global accounting for 56% of the holdings.
Seeking Alpha · 11/17 01:59
Theravance Bioph: Statement of changes in beneficial ownership of securities
Press release · 11/17 00:28
Theravance Bioph: Report of proposed sale of securities
Press release · 11/15 02:38
Weekly Report: what happened at TBPH last week (1106-1110)?
Weekly Report · 11/13 11:54
More
About TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath and others. Its pipeline of internally discovered programs is targeted to address unmet patient needs. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. Its Selective 5-HT4 Agonist (TD-8954) is a selective 5-HT4 receptor agonist, which is developed for the treatment of gastrointestinal motility disorders.

Webull offers Theravance Biopharma Inc stock information, including NASDAQ: TBPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TBPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TBPH stock methods without spending real money on the virtual paper trading platform.